An interesting new paper in BJU International has provided us with a somewhat different perspective on which patients with prostate cancer do and do not need preventive therapy (e.g., zoledronic acid/Zometa, dasatinib/Xgeva) to minimize risk for bone fractures. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, bone, deprivation, fracture, risk | 3 Comments »
Recent data from the Prostate Cancer Outcomes Study, which followed men diagnosed with prostate cancer for a total of 15 years after their diagnosis, have provided us with valuable information about risk for bone fractures in men with progressive disease. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, advanced, fracture, risk | 15 Comments »
According to a media release issued by Amgen earlier today, the U.S. Food & Drug Administration (FDA) has approved denosumab (marketed as both Prolia® and Xgeva®) as a treatment to increase bone mass in in men with non-metastatic prostate cancer who are already being treated with androgen deprivation therapy (ADT) and who are at high risk for bone fractures. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: approval, denosumab, fracture, Prevention | Leave a comment »
Clinical guidelines issued by the National Comprehensive Cancer Network recommend that prostate cancer patients being treated with androgen deprivation therapy (ADT) — either alone or in combination with radiation therapy — should be screened for osteoporosis and treatment to prevent deterioration of bone health associated with a decline in bone mineral density. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, DXA, fracture, FRAX, guideline, osteopenia, osteoporesis, Prevention | 4 Comments »
White race and low bone mineral density (osteoporosis) appear to be the only two of a dozen different potential risk factors that significantly increase the likelihood of vertebral (spinal and hip) fractures among men being treated with androgen deprivation therapy (ADT) for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, fracture, risk, vertebral | 1 Comment »
Toremifene is a selective estrogen receptor modulator or SERM. Some time ago, its developer (GTx, Inc.) initiated a Phase III clinical trial to investigate whether toremifene at a dose of 80 mg/day lowered risk for new vertebral fractures in prostate cancer patients being treated with androgen deprivation therapy (ADT). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: benefit, fracture, Prevention, risk, toremifene | 2 Comments »
On Tuesday, the US Food and Drug Administration (FDA) approved Amgen’s RANK-L inhibitor denosumab (Prolia®) for the treatment of postmenopausal women with osteoporosis at high risk for fracture. However, what they have not done (yet) … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: denosunam, fracture, Prevention, Prolia | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 